Intended for healthcare professionals

News

Covid-19: Antibody “signature” could predict risk of long covid

BMJ 2022; 376 doi: https://doi.org/10.1136/bmj.o245 (Published 28 January 2022) Cite this as: BMJ 2022;376:o245
  1. Jacqui Wise
  1. Kent

Researchers have identified an immunoglobulin “signature” that could be used to predict which patients are most at risk of developing post-acute covid syndrome (PACS), otherwise known as long covid.

In a multicentre prospective study, 175 patients with covid-19 and 40 healthy control group participants were followed for up to a year. More than half of the patients with covid reported long covid symptoms lasting longer than a month. Those who developed long covid were found to have lower levels of IgM and IgG3 antibodies than those who quickly recovered, found the research, published in Nature Communications.1 A history of asthma was also highly associated with PACS, the study found.

The researchers combined data on immunoglobulin concentrations with a patient’s age, history of asthma, and five symptoms during the primary infection to develop a PACS score that could predict the risk of …

View Full Text

Log in

Log in through your institution

Subscribe

* For online subscription